All In Biotech

Drug Trial Radar · NCT06881017

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping: an Umbrella Phase II Exploratory Clinical Study

Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Aug 1, 2029

Study completion Nov 1, 2029

Sponsor

Lead sponsor
China Medical University, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.

Conditions

  • Gastric Cancer
  • HER2 + Gastric Cancer
  • CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
  • PD-L1 Positive

Interventions

  • TrastuzumabDrug

    iv,d1

  • AdebrelimabDrug

    iv,d1,q3w

  • ApatinibDrug

    po,qd,d1-21,q3w

  • S-1Drug

    po,bid,d1-14,q3w

  • CapecitabineDrug

    po,bid,d1-14

  • OxaliplatinDrug

    iv,d1,q3w

  • zolbetuximabDrug

    iv,d1

  • SHR-A1811Drug

    iv,d1 ,q3w

  • SHR-A1904Drug

    iv,d1 ,q3w

  • SHR-1701Drug

    iv,d1 ,q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 2year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.